Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Ramandip Grewal, Lena Nguyen, Sarah A. Buchan, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization
Daniel R. Feikin, Melissa M. Higdon, Nick Andrews, et al.
Vaccine (2023) Vol. 41, Iss. 14, pp. 2329-2338
Open Access | Times Cited: 29
Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 29
Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review
Tasniah Begum, Nikolaos Efstathiou, Cara Bailey, et al.
Vaccine (2024) Vol. 42, Iss. 22, pp. 125993-125993
Open Access | Times Cited: 10
Estimates of SARS-CoV-2 Infections and Population Immunity After the COVID-19 Pandemic in Austria: Analysis of National Wastewater Data
Uwe Riedmann, Alena Chalupka, Lukáš Richter, et al.
The Journal of Infectious Diseases (2025)
Open Access
Effectiveness of SARS-CoV-2 testing strategies
KM Saif‐Ur‐Rahman, Nadra Nurdin, Ani Movsisyan, et al.
Cochrane library (2025) Vol. 2025, Iss. 2
Open Access
Assessment of COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Infection, Hospitalization and Death in Mexican Patients with Metabolic Syndrome from Northeast Mexico: A Multicenter Study
Beatriz Silva-Ramírez, Katia Peñuelas-Urquides, Brenda Leticia Escobedo-Guajardo, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 244-244
Open Access
Spatial analysis of COVID-19 incidence and mortality rates in northwest iran for future epidemic preparedness
Mohsen Soleimani, Ahmad Jalilvand
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study
Felippe Lazar Neto, Matt D. T. Hitchings, Avnika B. Amin, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100755-100755
Open Access | Times Cited: 4
Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
Allison Avrich Ciesla, Ryan E. Wiegand, Zachary Smith, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 10
COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follow-Up
Annalisa Rosso, Maria Elena Flacco, Graziella Soldato, et al.
Vaccines (2023) Vol. 11, Iss. 8, pp. 1325-1325
Open Access | Times Cited: 10
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Haruka Maeda, Nobuo Saito, Ataru Igarashi, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 213-225
Open Access | Times Cited: 3
The Transformative Potential of Lipid Nanoparticle–Protein Corona for Next-Generation Vaccines and Therapeutics
Augusto Amici, Daniela Pozzi, Cristina Marchini, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 11, pp. 5247-5253
Open Access | Times Cited: 8
Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection
Jong Eun Lee, Kwang Nam Jin, Hyunsook Hong, et al.
Radiology (2024) Vol. 310, Iss. 1
Closed Access | Times Cited: 2
The Impact of COVID-19 on Mortality and Clinical Characteristics in Hospitalized Patients With Peripheral Artery Disease in the Year 2020 in Germany
Sven M. Piepenburg, Mariya Maslarska, Klaus Kaier, et al.
Angiology (2024)
Closed Access | Times Cited: 2
Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection
Keon Young Lee, Kyoung‐Ho Song, Kyoung Hwa Lee, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3953-3960
Closed Access | Times Cited: 2
Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada
Ramandip Grewal, Sarah A. Buchan, Lena Nguyen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults
Nelson Lee, Lena Nguyen, Peter C. Austin, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1372-1382
Open Access | Times Cited: 7
Non-pharmaceutical interventions and vaccination during COVID-19 in Canada: Implications for COVID and non-COVID outcomes
Mehdi Ammi, Zachary Desson, Maeva Z. Doumbia
Health Policy and Technology (2023) Vol. 13, Iss. 1, pp. 100801-100801
Closed Access | Times Cited: 6
Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial
Xiaoqiang Liu, Zhonghan Sun, Zhongfang Wang, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102231-102231
Open Access | Times Cited: 6
Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults
Nelson Lee, Lena Nguyen, Peter C. Austin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
The Effect of COVID-19 Vaccination on Outpatient Antibiotic Prescribing in Older Adults: A Self-Controlled Risk-Interval Study
Sarah C J Jorgensen, Kevin A. Brown, Anna E. Clarke, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 375-381
Open Access | Times Cited: 1
The impact of comorbidity status in COVID-19 vaccines effectiveness before and after SARS-CoV-2 omicron variant in northeastern Mexico: a retrospective multi-hospital study
María Elena Camacho-Moll, Viviana Mata-Tijerina, Carlos Cuauhtémoc Gutiérrez-Salazar, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 1
Real-world effectiveness of mRNA COVID-19 vaccines in the elderly during the Delta and Omicron variants: Systematic review
Harvey Palalay, Riddhi Vyas, Barbara Tafuto
World Journal of Meta-Analysis (2023) Vol. 11, Iss. 5, pp. 167-180
Open Access | Times Cited: 3
Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand
Karan Thakkar, Júlia Spinardi, Moe H. Kyaw, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 860-870
Open Access | Times Cited: 2
Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection
Takeyuki Goto, Yong Chong, Naoki Tani, et al.
Vaccine (2023) Vol. 41, Iss. 47, pp. 7019-7025
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top